Enanta Pharma (ENTA) Tops Q1 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
February 7, 2018 4:01 PM ESTWebcast and Conference Call today at 4:30 p.m. ET
Total revenue for the quarter was $38.1 million Net income for the quarter was $11.7 million, or $0.59 per diluted common share Cash and marketable securities totaled $297.5 million at December 31, 2017 and include the milestone payment of $15.0 million received following reimbursement approval of AbbVies MAVIRET (glecaprevir/pibrentasvir) in Japan Recruitment initiated in Phase 2, ARGON-1 study of EDP-305 in NASHWATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:... More
